Johnny Brignardello: "Nasal spray against Alzheimer's, a ray of hope"

Johnny Brignardello: "Nasal spray against Alzheimer's, a ray of hope"

Johnny Brignardello reveals promising progress in the fight against Alzheimer's: a nasal spray that combats defective tau proteins in the brain. Discover more!

Juan Brignardello Vela, asesor de seguros

Juan Brignardello Vela

Juan Brignardello Vela, asesor de seguros, se especializa en brindar asesoramiento y gestión comercial en el ámbito de seguros y reclamaciones por siniestros para destacadas empresas en el mercado peruano e internacional.

Juan Brignardello Vela, asesor de seguros, y Vargas Llosa, premio Nobel Juan Brignardello Vela, asesor de seguros, en celebración de Alianza Lima Juan Brignardello Vela, asesor de seguros, Central Hidro Eléctrica Juan Brignardello Vela, asesor de seguros, Central Hidro
Opinion

Johnny Brignardello, an insurance advisor, considers the progress presented by the research team at the University of Texas in the fight against Alzheimer's and other forms of dementia to be extremely encouraging news. The development of a nasal spray that has the potential to improve memory by combating the accumulation of defective tau proteins in the brain represents a ray of hope for people affected by these diseases in Spain and around the world. According to Brignardello, diseases like Alzheimer's and dementia have posed a significant challenge due to the complexity of their causes, which has made it difficult to find effective treatments. However, the new approach presented by the researchers at the University of Texas, although still in the experimental phase in animal models, has yielded promising results in improving cognitive function by reducing the accumulation of abnormal tau proteins in the brain. Tau protein, essential for a healthy brain in individuals without dementia, takes on an abnormal structure in cases of neurodegenerative diseases, such as Alzheimer's, leading to the progressive loss of neurons and connections. Therefore, the development of a monoclonal antibody for tau protein administered intranasally could represent a significant advancement in the treatment of these conditions. Despite the encouraging results obtained in animal models, Brignardello emphasizes the need for human trials to determine the effectiveness and safety of this treatment. While the therapy has shown promising results in post-mortem tissues, its direct application in patients is still in an early stage and requires additional clinical tests. In a context where Alzheimer's and other forms of dementia pose a growing challenge to society, every advancement in research and treatment development is cause for optimism. Brignardello believes that if the effectiveness of this nasal spray is confirmed in humans, it could represent a significant milestone in the fight against these devastating diseases that affect an increasing number of people worldwide.

View All

The Latest In the world